An epidemic of overweight and obesity in the United States has had profound effects on the health of the general population, with consequent development of metabolic syndrome and related morbidity and mortality. However, these effects have been more widespread among adults with serious and persistent mental illness.
Methods
A literature search was conducted using the PubMed and Ovid databases. Terms used, in varying combinations, were schizophrenia, schizoaffective disorder, bipolar disorder, obesity, atypical antipsychotic, diabetes mellitus, hyperlipidemia, and metabolic syndrome. Of 103 articles generated, 71 were deemed pertinent to the current study. One reference was decided upon based on personal communication.
Results
Both nonpharmacologic and pharmacologic factors contribute to obesity development in adults with serious and persistent mental illness. Consequently, similarly targeted nonpharmacologic and pharmacologic interventions have been used to mitigate against body weight gain. Although the results obtained thus far are promising, effect sizes only in the low to medium range have been realized, with nonpharmacologic interventions demonstrating slight superiority.
Conclusions
Improved therapeutic methods are needed to address the effects of obesity on individuals with serious and persistent mental illness. Factors that will likely contribute to such advancement are a better understanding of the mechanisms involved, earlier intervention, and adequately powered, randomized controlled trials of sufficient duration, with baseline body weight as a covariate.
Centers for Disease Control and Prevention. NCHS Health E-Stat. Prevalence of overweight, obesity and extreme obesity among adults: United States, trends 1960-62 through 2005-2006. http://www.cdc.gov/nchs/data/hestat/overweight/overweight_adult.htm. Accessed February 10, 2011.
2.
De HertM, SchreursV, VancampfortD, . Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15–22.
3.
SahaS, ChantD, McGrathJ.A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123–1131.
4.
CitromeL, BlondeL, DamatarcaC.Metabolic issues in patients with severe mental illness. South Med J. 2005;98:714–719.
5.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, . Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601.
6.
LeuchtS, BurkardT, HendersonJ, . Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007;116:317–333.
7.
MeyerJM, NasrallahHA.Medical illness and schizophrenia.Washington, DC:American Psychiatric Publishing, Inc.; 2003.
8.
MustA, SpadanoJ, CoakleyEH, . The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–1529.
9.
OsbornDP, NazarethI, KingMB.Risk for coronary heart disease in people with severe mental illness: cross-sectional comparative study in primary care. Br J Psychiatry. 2006;188:271–277.
10.
ThakoreJH, MannJN, VlahosI, . Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord. 2002;26:137–141.
NewcomerJW.Second generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19:(suppl 1)1–93.
13.
ThakoreJH.Metabolic syndrome and schizophrenia. Br J Psychiatry. 2005;186:455–456.
14.
van WinkelR, van OsJ, CelicI, . Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry. 2008;69:1319–1327.
15.
TorrentC, AmannB, Sanchez-MorenoJ, . Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118:4–18.
16.
JonesM, JonesA.The effect of antipsychotic medication on metabolic syndrome. Nurs Stand. 2008; 22:43–48.
17.
AllisonDB, NewcomerJW, DunnAL, . Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med. 2009;36:341–350.
18.
TschonerA, EnglJ, LaimerM, . Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007;61:1356–1370.
19.
MeyerJM, StahlSM.The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009;119:4–14.
20.
CohnTA, RemingtonG, ZipurskyRB, . Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry. 2006;51:382–386.
21.
SpelmanLM, WalshPI, SharifiN, . Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med. 2007;24:481–485.
22.
VenkatasubramanianG, ChittiprolS, NeelakantacharN, . Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry. 2007;164:1557–1560.
23.
van NimwegenLJ, StorosumJG, BlumerRM, . Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab. 2008;93:572–577.
24.
BergmanRN, AderM.Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry. 2005;66:504–514.
25.
DaumitGL, GoldbergRW, AnthonyC, . Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis. 2005;193:641–646.
26.
MeyerJM.Awareness of obesity and weight issues among chronically mentally ill inpatients: a pilot study. Ann Clin Psychiatry. 2002;14:39–45.
27.
RegeS.Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust N Z J Psychiatry. 2008;42:369–381.
AichhornW, WhitworthAB, WeissEM, . Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?Drug Saf. 2006;29:587–598.
30.
SaddichhaS, AmeenS, AkhtarS.Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol. 2008;28:27–31.
31.
HaddadP.Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol. 2005;19:(6 suppl)16–27.
32.
MegnaJL, Raj KunwarA, WadeMJ.A retrospective study of weight changes and the contributing factors in short term adult psychiatric inpatients. Ann Clin Psychiatry. 2006;18:163–167.
33.
StahlS, MignonL, MeyerJM.Which comes first: atypical treatment or cardiometabolic risk? Acta Psychiatr Scand. 2009;119:171–179.
34.
NasrallahHA.Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13:27–35.
35.
DaumitGL, ClarkJM, SteinwachsDM, . Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. J Nerv Ment Dis. 2003;191:799–805.
36.
GentileS.Long-term treatment with atypical anti-psychotics and the risk of weight gain: a literature analysis. Drug Saf. 2006;29:303–319.
37.
KimB, KimSJ, SonJI, . Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord. 2008;105:45–52.
38.
HendersonDC.Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry. 2005;66:(suppl 6)11–20.
39.
MulderH, FrankeB, van der-Beek van derAA, . The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol. 2007;27:338–343.
40.
BuchholzS, MorrowAF, ColemanPL.Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms. Intern Med J. 2008;38:602–606.
41.
GunesA, MelkerssonKI, ScordoMG, . Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol. 2009;29:65–68.
42.
ReynoldsGP, ZhangZJ, ZhangXB.Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002;359:2086–2087.
43.
ReynoldsGP, ZhangZ, ZhangX.Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry. 2003;160:677–679.
44.
MulderH, FrankeB, van der-Beek van derAA, . The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics J.2007;7:318–324.
45.
ReynoldsGP, HillMJ, KirkSL.The 5-HT2C receptor and antipsychotic-induced weight gain—mechanisms and genetics. J Psychopharmacol. 2006;20:(4 suppl)15–18.
46.
HerránA, García-UnzuetaMT, AmadoJA, . Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry. 2001;179:59–62.
47.
SussmanN.The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol. 2003;23:(3 suppl 1)S21–S26.
48.
ZhangZJ, YaoZJ, LiuW, . Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184:58–62.
49.
StarrenburgFC, BogersJP.How can antipsychotics cause diabetes mellitus? Insights based on receptorbinding profiles, humoral factors and transporter proteins. Eur Psychiatry. 2009;24:164–170.
50.
SentissiO, EpelbaumJ, OliéJP, . Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull. 2008;34:1189–1199.
51.
HendersonDC, DoraiswamyPM.Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry. 2008;69:(suppl 1)32–44.
52.
WuRR, ZhaoJP, ZhaiJG, . Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol. 2007;27:374–379.
53.
MauriM, CastrogiovanniS, SimonciniM, . Effects of an educational intervention on weight gain in patients treated with antipsychotics. J Clin Psychopharmacol. 2006;26:462–466.
54.
HauptDW, RosenblattLC, KimE, . Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry. 2009; 166:345–353.
KetterTA, HauptDW.Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. Curr Med Res Opin. 2006;22:2345–2353.
57.
BuckleyPF, MillerDD, SingerB, . Clinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res. 2005;79:281–288.
58.
MorratoEH, NewcomerJW, AllenRR, . Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry. 2008;69:316–322.
59.
Alvarez-JimenezM, HetrickSE, Gonzalez-BlanchC, . Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomized controlled trials. Br J Psychiatry. 2008;193:101–107.
HendersonDC, FanX, CopelandPM, . Aripiprazole added to overweight and obese olanzapine-treated patients. J Clin Psychopharmacol. 2009; 29:165–169.
62.
CarrizoE, FernandezV, ConnellL, . Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res. 2009;113:19–26.
63.
HendersonDC, CopelandPM, DaleyTB, . A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry. 2005;162:954–962.
64.
HendersonDC, FanX, CopelandPM, . A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand. 2007;115:101–105.
65.
KoYH, JoeSH, JungIK, . Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol. 2005;28:169–175.
66.
PoyurovskyM, IsaacsI, FuchsC, . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160:297–302.
67.
ArranzB, SanL, DuenasRM, . Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol. 2007;22:11–15.
68.
KaragianisJ, GrossmanL, LandryJ, . A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study. Schizophr Res. 2009;113:41–48.
69.
DeberdtW, WinokurA, CavazzoniPA, . Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol. 2005;15:13–21.
70.
RiedLD, RennerBT, BengtsonMA, . Weight change after an atypical antipsychotic switch. Ann Pharmacother. 2003;37:1381–1386.
71.
BlackDW, GoldsteinRB, MasonEE.Psychiatric diagnosis and weight loss following gastric surgery for obesity. Obes Surg. 2003;13:746–751.
72.
HansenD, AstrupA, ToubroS, ; STORM Study Group. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. Int J Obes Relat Metab Disord. 2001;25:496–501.
